Long-Term Effect of 10 mg Versus 20 mg Rimonabant in Overweight or Obese Patients

Exclusion Criteria

• •Weight loss \> 5 kg within 3 months prior to screening Visit.
• •Presence of any clinically significant endocrine disease including the presence of type 1 diabetes
• •Presence of any severe medical or psychological condition that, in the opinion of the investigator, would compromise the patient's safe participation including uncontrolled serious psychiatric illness such a major depression within the last 2 years, and history of other severe psychiatric disorders
• •Previous participation in a clinical study with rimonabant
• •Administration of other investigational drugs, anti-obesity drugs or other drugs for weight reduction
• •Pregnancy and absence of effective contraceptive method for females of childbearing potential
• •Exenatide
• •Insulin therapy
• •Recent change or need for change in the oral antidiabetic treatment
• •Recent change or need for change in the lipid lowering treatment
• •Presence of severe renal or hepatic impairment
• •The above information is not intented to contain all considerations relevant to a patient's potential participation in a clinical trial.